Dana-Farber Cancer Institute

Articles

New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science

September 1st 2025

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

August 27th 2025

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute

August 21st 2025

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma

August 11th 2025

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Global Rise in Many Early-Onset GI Cancers Detailed in Two Dana-Farber Reviews, With Colorectal Cancer Leading the Trend

July 25th 2025

Fewer than 1 in 5 U.S. adults aged 45-49 screened for colorectal cancer, despite guidelines

Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer

July 4th 2025

A study led by Dana-Farber Cancer Institute researchers found that chemoimmunotherapy before surgery for stage III NSCLC can help make surgery possible.

Novel Cancer Screening Test for Veterans Now Being Offered at Dana-Farber Cancer Institute

July 3rd 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

June 13th 2025

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor

May 27th 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Dana-Farber Launches the Ning Zhao & Ge Li Simulation Center to Develop and Train the Next Generation of Oncology Nurses

May 5th 2025

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

April 28th 2025

Dana-Farber Cancer Institute highlights research being presented at the 2025 AACR Annual Meeting.

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

April 23rd 2025

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards

April 16th 2025

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

Vish Viswanath, PhD, of Dana-Farber Cancer Institute, Elected as Fellow of the American Association for the Advancement of Science

April 14th 2025

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells

April 7th 2025

A study showed transcription factor networks disproportionately enrich for heritability of blood cell phenotypes.

New Patient-Partnered Research Project for Translocation Renal Cell Carcinoma Launches

March 17th 2025

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, is launching a project focused on translocation renal cell carcinoma.

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer

February 10th 2025

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

AI Model Learns Generalized 'Language' of Regulatory Genomics, Predicts Cellular Stories

February 5th 2025

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence

January 28th 2025

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.